Jasinski Lawrence J 4

What Happened

• Lawrence J. Jasinski, a director of Lemaitre Vascular, was credited with a total of 3.445 dividend-equivalent rights on March 26, 2026. The filing lists five derivative acquisitions (0.394, 0.472, 0.643, 0.728 and 1.208 shares) reported as awards/grants at $0.00 each (total reported value $0).
• These items are dividend equivalent rights (DERs) tied to previously granted restricted stock units (RSUs) and performance share units (PSUs); they accrue and vest proportionately with those awards rather than representing an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-26; Form 4 filed: 2026-03-30 (filing appears within the standard two-business-day window).
• Reported items: five derivative award entries totaling 3.445 shares; price per unit $0.00; total reported cash value $0.
• Footnotes indicate the DERs relate to awards granted on 12/8/2023, 12/6/2024 and 12/10/2025 (combination of RSUs and PSUs; each DER equals the economic equivalent of one common share).
• Shares owned after the transaction: not specified in the provided filing.

Context

• These are not open-market purchases or sales — they are dividend-equivalent credits tied to existing equity awards and typically reflect accruals that convert into shares (or cash) as the underlying awards vest.
• Such dividend-equivalent accruals are common and do not by themselves indicate a buy/sell signal; they simply record the allocation of small fractional share equivalents to the insider.